An official website of the United States government
Expand existing large scale, open-science molecular profiling efforts by:
- Increasing the bandwidth for the generation and analysis of high-quality molecular data (genetics and epigenetics, transcriptomics, proteomics, metabolomics, lipidomics, glycomics, exposome, etc.) from human tissues and cell lines.
- Investing in the development of methods for multi-scale modeling across -omics data-types.
- Ensuring that diverse cohorts and special populations are included and prioritized in these efforts.
2023 RFA-AG-13-013: Interdisciplinary Approach to Identification and Validation of Novel Therapeutic Targets for Alzheimer's Disease (R01) RFA-AG-15-010: Interdisciplinary Research to Understand the Vascular Contributions to Alzheimer's Disease (R01) RFA-AG-15-011: Biomarkers of Alzheimer’s Disease in Down Syndrome (R01) RFA-AG-17-061: Interdisciplinary Research to Understand the Complex Biology of Resilience to Alzheimer’s Disease Risk (R01) RFA-AG-18-013: Continuation of the AMP AD Target Discovery and Preclinical Validation Consortium RFA-AG-18-014: Limited Competition: Data Coordinating Center for the Accelerating Medicines Partnership Target Discovery and Preclinical Validation Consortium AMP AD (U24) 1.E Achieved DN 2018 AD Summit: 3B Blog: NIAGADS! We have data! News: Decoding the molecular ties between vascular disease and Alzheimer’s News: NIH Supports new studies to find Alzheimer’s biomarkers in Down Syndrome Blog: Working from home? Check out new genetics data for Alzheimer’s disease research! Workshop: Alzheimer’s Disease, Genetics Global Symposium Workshop: Alzheimer’s Disease, Genetics Global Symposium Agenda Population Studies and Precision Medicine Alzheimer’s Biomarkers Consortium- Down Syndrome (ABC-DS) Alzheimer’s Disease Sequencing Project (ADSP) AMP AD – Target Discovery and Preclinical Validation AMP-AD 2.0 Precision Medicine Approach to Target and Biomarker Discovery Molecular Mechanisms of the Vascular Etiology of Alzheimer's Disease (M²OVE-AD) Consortium Next Generation Translational Proteomics for Alzheimer’s Disease and Related Dementias Alzheimer variants: Propagation of shared functional changes across cellular networks The Emory Healthy Brain Study: Discovering Predictive Biomarkers for Alzheimer's Disease
- Provide supplemental funding to at least 6 existing projects/programs that are generating high-dimensional on human aging cohorts to close key molecular data gaps, including molecular profiling for post-translational modification, methods development for multi-scale modeling, and inclusion of samples from diverse cohorts and special populations.
- Ensure that existing and newly funding projects continue to operate under open science principles.
Summary of Key Accomplishments
Through the Accelerating Medicines Partnership for Alzheimer’s Disease (AMP-AD), the HABS-HD (Health and Aging Brain Study- Health Disparities) and ABC-DS (Alzheimer’s Biomarkers Consortium - Down Syndrome) consortia, NIA is supporting the generation of various types of molecular data from biosamples collected from diverse as well as special populations (African American and Latino Cohorts; individuals with Down Syndrome) known to be at higher risk of AD/dementia. These programs operate under open science principles, i.e., the data are being made available rapidly to the greater research community in the academic and biotech/industry sectors. NIA supports the development of advanced analytical methods that will use these biological datasets to build mathematical models of the disease that reflect the various mechanisms of disease risk and resilience across different populations.
The key accomplishments summary is current as of March 2022.